PRPH ProPhase Labs Inc

ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19

ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19

UNIONDALE, NY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be presenting third quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on November 19, 2025, at 2:00 pm EST.

A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors and other individual followers to register and attend this live event.

Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on The Company’s Investor website.

REGISTER HERE:

  • To ensure smooth connectivity, please access this link using the latest version of Google Chrome.



About ProPhase Labs Inc.

ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development, such as our potentially life-saving test for the early detection of esophageal cancer, and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value.

Media Relations Contact:

ProPhase Labs, Inc.

Investor Relations Contact:

Dave Gentry, CEO

RedChip Companies, Inc.

1-800-REDCHIP (733-2447)

1-407-644-4256

Retail Investor Relations Contact:

Renmark Financial Communications

John Boidman:

Tel.: (416) 644-2020 or (212) 812-7680



EN
18/11/2025

Underlying

PRPHProPhase Labs Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProPhase Labs Inc

 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Provides Update on Convertible Debt Conversions, Capital...

ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company’s underlying asset base. The Company believes that recent volatility in its stock price has been driven by a combination of short-term technical factors, including the accelerated conversion and resale of a significant portion of its outstanding convertible debt, the completion of a 1-f...

January 5, 2026 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with A...

ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call today at 10:00 a.m. ET UNIONDALE, NY, Dec. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase") and Advanced Biological Laboratories S.A. ("ABL"), a European biotechnology and MedTech group, today announced that they have entered into a non-binding Letter of Intent ("LOI...

December 19, 2025 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on...

Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on December 1 UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature ProPhase Lab’s Chairman and CEO Ted Karkus. Attendees will gain an in-depth look at ProPhase’s dynamic portfolio of high-growth healthcare assets spanning molecular diagnostics, genomics, and consumer health. Karkus will highlight recent milestones, including full U.S. patent approv...

November 26, 2025 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Reported Results for the Third Quarter Ended September 3...

ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET. ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important. Crown Medical Achieves Final Hurdle. Appointed Special Counsel to Launch Litigation Against Insurance Companies. First Settlement Completed. Reiterates $50 MILLION Net A/R Goal Next-Phase Commercialization of BE-Smart™ Underway Following Landmark Study Published in the Official Journal of the American...

November 19, 2025 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on...

ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19 UNIONDALE, NY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be presenting third quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on November 19, 2025, at 2:00 pm EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors and othe...

November 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch